ArticleClinical epidemiology2022
Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030.
Article in Clinical epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Prospective randomized trial comparing mini-percutaneous nephrolithotomy, retrograde intrarenal surgery, and shock wave lithotripsy for treatment of medium-sized high-density renal stones.International urology and nephrology · 2026Trial
- Prevalence and biomarker profiles of HBV/HDV coinfection and occult HBV infection among patients attending Bimbilla Hospital, Northern Ghana.BMC infectious diseases · 2026Article
- Hepatitis B burden in the Middle East and North Africa region, 1990-2030: trends, projections, and age-period-cohort analysis.BMC infectious diseases · 2026Article
- Hepatitis B in China: the analysis of mortality and burden of disease trends from 2008 to 2021.BMC public health · 2026Article
- A toehold-triggered switchable three-way junction protective nanoprobe for RNase H-assisted HBV rcDNA detection.Journal of nanobiotechnology · 2026Article
- Population immunity to hepatitis B virus and infection marker seroprevalence in Belgrade, Serbia.Frontiers in public health · 2026Article
- Age-period-cohort analysis of pulmonary tuberculosis epidemiological trends from 2005 to 2024 and forecasts for 2035 in Sichuan Province, China.Frontiers in public health · 2026Article
- Article
- Prevalence and Diagnostic Determinants of Hepatitis B Infection Among Saudi Adults: Implications for Targeted Screening and Early Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Long-Term Epidemiology of Hepatitis B and Impact of Vaccination in the Autonomous Province of Vojvodina, Serbia: A Population-Based Study.Microorganisms · 2025Article
- Neonatal vaccination and HBV prevalence: evidence from Esfandiar village, Iran.Iranian journal of microbiology · 2025Article
- Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study.BMC infectious diseases · 2025Article
- The disease burden of kidney cancer in Asian countries and regions from 1990 to 2021: a study based on the Global Burden of Disease database.Translational andrology and urology · 2025Article
- An analysis of trends in the burden of ischemic stroke caused by air pollution in China between 1990 and 2021.BMC public health · 2025Article
- Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.Journal of viral hepatitis · 2025Article
- Health economic evaluation of newborn hepatitis B immunization prevention strategies in Ningbo: a Markov modeling study.Frontiers in public health · 2025Article
- Comparative analysis of different stroke subtype burden and future trends over 15 years in China and globally from 1990 to 2021.Frontiers in neurology · 2025Article
- Trends and multi-model prediction of hepatitis B incidence in Xiamen.Infectious Disease Modelling · 2024Article
- Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Despite widespread vaccination against hepatitis B and availability of antiviral drugs, hepatitis B remained a major global public health problem. Therefore, an improved understanding of the burden of hepatitis B was required to help design strategies for global intervention. Methods: Data on hepatitis B was collected by the Global Burden of Disease (GBD) 2019 database from 1990 to 2019. Age-standardized incidence rates (ASIR), mortality rates (ASMR) and disability-adjusted life year rates (ASDR) for hepatitis B were extracted from GBD 2019 and stratified by age, level of regionals and country. Estimated annual percentage changes (EAPC) of ASIR, ASMR and ASDR were calculated to quantify the temporal trends in hepatitis B. Results: Globally, ASIR showed a continuous downward trend, from 1552.2 in 1990 to 1010.0 per 100,000 persons in 2019, with an annual decrease of 1.52% (95% CI -1.66--1.38). ASMR showed a persistent decline, declining by nearly half in 2019 compared to 1990 (6.7 vs 12.4 per 100,000 persons), with an annual decrease of 2.55% (95% CI -2.74--2.35). ASDR showed a continuing downward trend, and the EAPC was -2.55% (95% CI -2.74--2.35). This decreasing pattern was heterogeneous across regions and countries. Hepatitis B related deaths increased significantly in high socio-demographic index countries such as UK, USA, and Canada. The ARIMA model estimates a 36.14% and 6.00% decrease in ASIR and ASMR, respectively, by 2030 compared to 2015. Conclusion: Global hepatitis B morbidity and mortality rates decreased significantly from 1990 to 2019, but with a high degree of heterogeneity among regions and countries. It was still far from achieving the WHO goal of elimination of viral hepatitis by 2030, especially mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.